Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 55 | 2025 | 722 | 6.260 |
Why?
|
| Depressive Disorder | 11 | 2017 | 457 | 1.610 |
Why?
|
| Cognition Disorders | 10 | 2022 | 556 | 1.460 |
Why?
|
| Anxiety Disorders | 10 | 2017 | 730 | 1.290 |
Why?
|
| Stress Disorders, Post-Traumatic | 5 | 2023 | 673 | 1.110 |
Why?
|
| REM Sleep Behavior Disorder | 2 | 2025 | 19 | 0.920 |
Why?
|
| Amnesia | 1 | 2025 | 20 | 0.880 |
Why?
|
| Dissociative Disorders | 1 | 2025 | 13 | 0.880 |
Why?
|
| Mental Recall | 1 | 2025 | 138 | 0.830 |
Why?
|
| Anxiety | 12 | 2019 | 1001 | 0.830 |
Why?
|
| Prefrontal Cortex | 2 | 2025 | 212 | 0.820 |
Why?
|
| Psychiatric Status Rating Scales | 13 | 2018 | 828 | 0.780 |
Why?
|
| Aggression | 1 | 2024 | 216 | 0.720 |
Why?
|
| Mental Disorders | 6 | 2016 | 890 | 0.700 |
Why?
|
| Hippocampus | 2 | 2025 | 793 | 0.630 |
Why?
|
| Cognitive Dysfunction | 2 | 2022 | 336 | 0.630 |
Why?
|
| Depression | 16 | 2020 | 1317 | 0.620 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 288 | 0.600 |
Why?
|
| Pituitary Neoplasms | 1 | 2020 | 80 | 0.590 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 204 | 0.570 |
Why?
|
| Dystonia | 2 | 2020 | 169 | 0.490 |
Why?
|
| Middle Aged | 41 | 2025 | 28383 | 0.470 |
Why?
|
| Veterans | 6 | 2025 | 1792 | 0.470 |
Why?
|
| Cognition | 3 | 2020 | 812 | 0.460 |
Why?
|
| Dementia | 3 | 2014 | 429 | 0.420 |
Why?
|
| Psychotic Disorders | 3 | 2019 | 149 | 0.410 |
Why?
|
| Humans | 69 | 2025 | 130422 | 0.400 |
Why?
|
| Panic Disorder | 2 | 2011 | 52 | 0.390 |
Why?
|
| Aged | 34 | 2025 | 20894 | 0.390 |
Why?
|
| Health Services | 1 | 2012 | 69 | 0.370 |
Why?
|
| Health Status | 2 | 2012 | 367 | 0.370 |
Why?
|
| Surveys and Questionnaires | 9 | 2017 | 4002 | 0.370 |
Why?
|
| Illusions | 1 | 2012 | 7 | 0.360 |
Why?
|
| Delusions | 1 | 2012 | 17 | 0.360 |
Why?
|
| Drug Utilization | 1 | 2013 | 162 | 0.360 |
Why?
|
| Hallucinations | 1 | 2012 | 26 | 0.360 |
Why?
|
| Disclosure | 1 | 2013 | 150 | 0.350 |
Why?
|
| Family Health | 3 | 2011 | 242 | 0.350 |
Why?
|
| Male | 46 | 2025 | 64527 | 0.350 |
Why?
|
| Nootropic Agents | 2 | 2009 | 27 | 0.340 |
Why?
|
| Comorbidity | 9 | 2020 | 1587 | 0.330 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2010 | 32 | 0.330 |
Why?
|
| Memory Disorders | 3 | 2020 | 204 | 0.320 |
Why?
|
| Female | 44 | 2025 | 70285 | 0.310 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 6781 | 0.300 |
Why?
|
| Propylamines | 1 | 2009 | 8 | 0.300 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2009 | 29 | 0.290 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2014 | 361 | 0.280 |
Why?
|
| Prevalence | 8 | 2020 | 2685 | 0.230 |
Why?
|
| Severity of Illness Index | 11 | 2017 | 3033 | 0.220 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2025 | 5 | 0.220 |
Why?
|
| Memory, Episodic | 1 | 2025 | 26 | 0.220 |
Why?
|
| Prodromal Symptoms | 1 | 2025 | 9 | 0.220 |
Why?
|
| Adult | 20 | 2025 | 31127 | 0.220 |
Why?
|
| Psychometrics | 5 | 2013 | 669 | 0.210 |
Why?
|
| Neuropsychological Tests | 8 | 2020 | 955 | 0.210 |
Why?
|
| Indans | 1 | 2004 | 52 | 0.200 |
Why?
|
| Violence | 1 | 2024 | 127 | 0.190 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2004 | 87 | 0.190 |
Why?
|
| Cross-Sectional Studies | 11 | 2020 | 3803 | 0.190 |
Why?
|
| Mental Health Services | 3 | 2015 | 275 | 0.190 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2016 | 718 | 0.180 |
Why?
|
| Piperidines | 1 | 2004 | 230 | 0.180 |
Why?
|
| Memory | 3 | 2020 | 354 | 0.170 |
Why?
|
| Pilot Projects | 5 | 2025 | 1452 | 0.170 |
Why?
|
| Patient Health Questionnaire | 1 | 2020 | 16 | 0.160 |
Why?
|
| Attention | 2 | 2020 | 192 | 0.160 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2020 | 9 | 0.160 |
Why?
|
| Internationality | 1 | 2020 | 128 | 0.150 |
Why?
|
| Parasomnias | 1 | 2019 | 4 | 0.150 |
Why?
|
| Unconsciousness | 1 | 2019 | 27 | 0.150 |
Why?
|
| Combat Disorders | 1 | 2019 | 22 | 0.150 |
Why?
|
| Dreams | 1 | 2019 | 24 | 0.150 |
Why?
|
| Psychotropic Drugs | 2 | 2011 | 116 | 0.150 |
Why?
|
| Fatigue | 3 | 2010 | 195 | 0.150 |
Why?
|
| Tremor | 1 | 2020 | 125 | 0.150 |
Why?
|
| Activities of Daily Living | 3 | 2015 | 378 | 0.150 |
Why?
|
| Encephalitis | 1 | 2020 | 121 | 0.140 |
Why?
|
| Evaluation Studies as Topic | 2 | 2008 | 227 | 0.140 |
Why?
|
| Sleep | 1 | 2021 | 370 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2015 | 771 | 0.140 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 101 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 139 | 0.130 |
Why?
|
| Brain Concussion | 1 | 2019 | 248 | 0.130 |
Why?
|
| Public Housing | 1 | 2016 | 8 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3388 | 0.120 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2009 | 220 | 0.120 |
Why?
|
| Dystonic Disorders | 1 | 2017 | 97 | 0.120 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 322 | 0.120 |
Why?
|
| Age of Onset | 6 | 2014 | 598 | 0.120 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 158 | 0.120 |
Why?
|
| Psychiatry | 1 | 2019 | 269 | 0.120 |
Why?
|
| Apathy | 1 | 2015 | 12 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2010 | 3425 | 0.110 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 245 | 0.110 |
Why?
|
| Mass Screening | 1 | 2020 | 805 | 0.110 |
Why?
|
| Motor Skills Disorders | 2 | 2014 | 9 | 0.100 |
Why?
|
| Phenotype | 2 | 2017 | 4474 | 0.100 |
Why?
|
| Heterozygote | 3 | 2014 | 720 | 0.100 |
Why?
|
| Torticollis | 1 | 2014 | 56 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2011 | 1215 | 0.100 |
Why?
|
| ROC Curve | 2 | 2020 | 606 | 0.100 |
Why?
|
| Movement | 1 | 2014 | 145 | 0.100 |
Why?
|
| Research Design | 2 | 2015 | 718 | 0.100 |
Why?
|
| Role | 1 | 2013 | 26 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 3815 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2016 | 429 | 0.100 |
Why?
|
| Mental Health | 2 | 2014 | 369 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 1125 | 0.090 |
Why?
|
| Schizophrenia | 1 | 2015 | 326 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2013 | 189 | 0.090 |
Why?
|
| Convergence, Ocular | 1 | 2011 | 2 | 0.090 |
Why?
|
| Dopamine Agents | 1 | 2011 | 27 | 0.090 |
Why?
|
| Independent Living | 1 | 2012 | 66 | 0.090 |
Why?
|
| Point Mutation | 2 | 2010 | 334 | 0.090 |
Why?
|
| Ocular Motility Disorders | 1 | 2011 | 38 | 0.090 |
Why?
|
| Behavior Therapy | 1 | 2013 | 271 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2020 | 6423 | 0.080 |
Why?
|
| Oculomotor Muscles | 1 | 2011 | 80 | 0.080 |
Why?
|
| Antidepressive Agents | 1 | 2013 | 328 | 0.080 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2010 | 29 | 0.080 |
Why?
|
| Database Management Systems | 1 | 2010 | 26 | 0.080 |
Why?
|
| Societies, Scientific | 1 | 2010 | 24 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2013 | 482 | 0.080 |
Why?
|
| Comparative Effectiveness Research | 1 | 2010 | 70 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2010 | 74 | 0.080 |
Why?
|
| Glucosylceramidase | 1 | 2010 | 35 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 701 | 0.080 |
Why?
|
| United States | 6 | 2019 | 11827 | 0.080 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2009 | 16 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2015 | 769 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 200 | 0.070 |
Why?
|
| Genetic Counseling | 1 | 2010 | 236 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2009 | 86 | 0.070 |
Why?
|
| Antiparkinson Agents | 1 | 2009 | 63 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1205 | 0.070 |
Why?
|
| Mutation | 3 | 2010 | 6131 | 0.070 |
Why?
|
| Substantia Nigra | 1 | 2008 | 35 | 0.070 |
Why?
|
| Movement Disorders | 1 | 2010 | 218 | 0.070 |
Why?
|
| alpha-Synuclein | 2 | 2005 | 141 | 0.060 |
Why?
|
| Caregivers | 1 | 2013 | 572 | 0.060 |
Why?
|
| Education | 1 | 2007 | 111 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2020 | 5069 | 0.060 |
Why?
|
| Stroke | 1 | 2014 | 1055 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2016 | 12860 | 0.060 |
Why?
|
| Motivation | 1 | 2008 | 328 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2016 | 937 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2007 | 1889 | 0.060 |
Why?
|
| Bipolar Disorder | 1 | 2009 | 311 | 0.060 |
Why?
|
| Deep Brain Stimulation | 1 | 2011 | 446 | 0.060 |
Why?
|
| Emotions | 1 | 2008 | 349 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 1164 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 336 | 0.060 |
Why?
|
| Lewy Body Disease | 1 | 2004 | 16 | 0.060 |
Why?
|
| Consensus | 1 | 2007 | 530 | 0.050 |
Why?
|
| Plaque, Amyloid | 1 | 2004 | 67 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3112 | 0.050 |
Why?
|
| Quality of Life | 4 | 2019 | 2071 | 0.050 |
Why?
|
| Risk | 2 | 2020 | 729 | 0.050 |
Why?
|
| Polysomnography | 1 | 2025 | 157 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 2919 | 0.050 |
Why?
|
| Alzheimer Disease | 2 | 2015 | 875 | 0.050 |
Why?
|
| Genetic Testing | 4 | 2010 | 1100 | 0.050 |
Why?
|
| Cerebellar Diseases | 1 | 2002 | 78 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 451 | 0.040 |
Why?
|
| Huntington Disease | 1 | 2002 | 122 | 0.040 |
Why?
|
| Aging | 1 | 2008 | 1253 | 0.040 |
Why?
|
| International Cooperation | 2 | 2011 | 156 | 0.040 |
Why?
|
| Genotype | 3 | 2010 | 2605 | 0.040 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2 | 2010 | 21 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 426 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1627 | 0.040 |
Why?
|
| Simplexvirus | 1 | 2020 | 103 | 0.040 |
Why?
|
| Afghan Campaign 2001- | 1 | 2019 | 120 | 0.040 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2019 | 128 | 0.040 |
Why?
|
| Risk Factors | 4 | 2015 | 10942 | 0.040 |
Why?
|
| Vision, Ocular | 1 | 2020 | 116 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 1086 | 0.040 |
Why?
|
| Community Mental Health Services | 1 | 2019 | 43 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2010 | 739 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 441 | 0.030 |
Why?
|
| Neurons | 1 | 2008 | 2010 | 0.030 |
Why?
|
| Young Adult | 3 | 2020 | 9995 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2014 | 1223 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 325 | 0.030 |
Why?
|
| Disease Progression | 2 | 2014 | 2205 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2106 | 0.030 |
Why?
|
| Telephone | 1 | 2015 | 110 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 555 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 188 | 0.030 |
Why?
|
| Nurses | 1 | 2015 | 73 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 428 | 0.030 |
Why?
|
| Touch | 1 | 2014 | 38 | 0.030 |
Why?
|
| Posture | 1 | 2014 | 121 | 0.030 |
Why?
|
| Electromyography | 1 | 2014 | 139 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2014 | 180 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2015 | 441 | 0.020 |
Why?
|
| Adolescent | 3 | 2020 | 20754 | 0.020 |
Why?
|
| Age Factors | 2 | 2010 | 2835 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 813 | 0.020 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 19 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2013 | 209 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2016 | 480 | 0.020 |
Why?
|
| Carbidopa | 1 | 2011 | 17 | 0.020 |
Why?
|
| Sensation | 1 | 2011 | 48 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2015 | 555 | 0.020 |
Why?
|
| Levodopa | 1 | 2011 | 91 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1485 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 1395 | 0.020 |
Why?
|
| Syndrome | 1 | 2013 | 1160 | 0.020 |
Why?
|
| Jews | 1 | 2010 | 34 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1334 | 0.020 |
Why?
|
| Decision Making | 1 | 2015 | 687 | 0.020 |
Why?
|
| Executive Function | 1 | 2010 | 126 | 0.020 |
Why?
|
| Visual Perception | 1 | 2010 | 127 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 269 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 759 | 0.020 |
Why?
|
| Telemedicine | 1 | 2015 | 511 | 0.020 |
Why?
|
| Physicians | 1 | 2015 | 634 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2011 | 529 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 788 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 184 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1233 | 0.020 |
Why?
|
| Hospitals | 1 | 2011 | 439 | 0.020 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2007 | 13 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2008 | 98 | 0.020 |
Why?
|
| Publishing | 1 | 2007 | 107 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 1399 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 1799 | 0.010 |
Why?
|
| Synucleins | 1 | 2004 | 11 | 0.010 |
Why?
|
| Formates | 1 | 2004 | 5 | 0.010 |
Why?
|
| Lewy Bodies | 1 | 2004 | 13 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 606 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 2298 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1605 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 764 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2009 | 1556 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2010 | 17614 | 0.010 |
Why?
|
| tau Proteins | 1 | 2004 | 258 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1607 | 0.010 |
Why?
|
| Prognosis | 1 | 2009 | 4894 | 0.010 |
Why?
|
| Personality Disorders | 1 | 2002 | 170 | 0.010 |
Why?
|
| Brain | 1 | 2010 | 3186 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 33892 | 0.000 |
Why?
|